CoMind
Focus: CoMind is a UK-based biotechnology company developing a non-invasive brain monitoring system focused on neurology applications. The company is public-stage with early feasibility studies underway.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$102.5M
Open Jobs
4-5 this month
Cooling — net -5 jobs in 30d
1 added, 6 removed. Slower than typical.
Should You Work at CoMind?
AI assessmentCoMind offers early-stage neurotech upside for risk-tolerant professionals, but the lack of clinical data, small team size, and financial opacity warrant thorough due diligence before committing.
Why Work Here
- Ground-floor opportunity in an emerging neurotech space with a novel non-invasive monitoring technology
- Early-stage pipeline with only 1 active trial suggests potential for rapid advancement and visibility
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CoMind Early Feasibility Study
Intracranial PressureClinical Trials (1)
NCT06368648CoMind Early Feasibility Study
N/AHelp build intelligence for CoMind
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.